Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × dostarlimab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 15 Neoplasms 14 Carcinoma, Non-Small-Cell Lung 9 Ovarian Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Neoplasm Metastasis 6 Uterine Cervical Neoplasms 5 Head and Neck Neoplasms 5 Melanoma 4 Colonic Neoplasms 4 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Breast Neoplasms 3 Stomach Neoplasms 2 Osteosarcoma 2 Multiple Myeloma 2 Lung Neoplasms 2 Locally Advanced Rectal Cancer (LARC) 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Neuroendocrine 2 Carcinoma 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma, Clear Cell 1

Interventions

Cyclophosphamide 133 Dexamethasone 107 Rituximab 70 fludarabine 65 Lenalidomide 59 Cytarabine 59 Gemcitabine 54 fludarabine phosphate 49 Bortezomib 48 pembrolizumab 46 venetoclax 45 Etoposide 44 Paclitaxel 43 Carboplatin 42 Cisplatin 41 pomalidomide 39 Peripheral Blood Stem Cell Transplantation 38 Filgrastim 37 Radiotherapy 35 Bevacizumab 33 Melphalan 31 Busulfan 31 Calcium Dobesilate 29 carfilzomib 28 Cyclosporine 28 Methotrexate 27 Azacitidine 26 Nivolumab 25 Mycophenolic Acid 25 Temozolomide 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡